The US Food and Drug Administration has raised some concerns about clinical trial data of TransMedics’ Organ Care System (OCS) Liver System as experts are scheduled to deliberate during a public panel meeting.
The FDA’s gastroenterology and urology devices advisory committee is set to convene a meeting on 14 July to discuss whether...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?